News
In collaboration with G42 Healthcare and Abu Dhabi Health Services (SEHA), Department of Health Abu Dhabi announces that those who want to volunteer can visit the screening and testing facility at ADNEC without making an appointment
2 Aug, 2020: The Department of Health Abu Dhabi in collaboration with G42 Healthcare and Abu Dhabi Health Services (SEHA) have announced the opening of a new purpose-built, walk-in registration, screening and testing facility at ADNEC for volunteers who want to participate in the world's first clinical Phase III trial of an inactivated vaccine to combat COVID-19. Those who want to volunteer can visit the facility directly without making an appointment.
ADNEC has the size and resources to process up to 1000 volunteers a day, individuals who have already registered online but have not yet had a follow-up call can also benefit from the walk-in clinic if they wish to visit and receive on-site screening and the first vaccination three days after receiving a negative test for COVID-19. The facility will only be open to individuals who are resident in Abu Dhabi.
Since the programme commenced on 16th July, thousands of people from every Emirate have volunteered and registered to become part of the trials. The new facility will help to make it even simpler for volunteers in Abu Dhabi to register, be screened on site and then, if eligible, be invited to return in a few days to take the first shot of the vaccine.
Abu Dhabi-based G42 Healthcare is managing the clinical trial process under the supervision of the Department of Health Abu Dhabi and in coordination with Abu Dhabi Health Services (SEHA), whose specialized staff runs the on-site operations.
A feasibility evaluation for setting up similar sites in other part of the UAE to to improve convenience for volunteers is currently being conducted.
For more information you can visit http://www.4humanity.ae and stay up to date with announcements on social media by following @AShot4Humanity and #4humanity on Twitter, Facebook and Instagram.
The Phase III clinical trial for the inactivated vaccine follows the success of the Phase I and Phase II trials conducted by Sinopharm in China, which resulted in 100% of the volunteers generating antibodies after two doses in 28 days. The Phase III trials are open to healthy volunteers aged between 18 and 60 living in the UAE and will last between six to eight months, with the volunteers required to be available for follow ups during this time.